Carbohydrate-binding antibodies and carbohydrate-based vaccines are being actively pursued as targeted immunotherapies for a broad range of cancers. Recognition of tumor-associated carbohydrates (glycans) by antibodies is predominantly towards terminal epitopes on glycoproteins and glycolipids on the surface of cancer cells. Crystallography along with complementary experimental and computational methods have been extensively used to dissect antibody recognition of glycan epitopes commonly found in cancer. We provide an overview of the structural biology of antibody recognition of tumor-associated glycans and propose potential rearrangements of these targets in the membrane that could dictate the complex biological activities of these antibodies against cancer cells.
CITATION STYLE
Soliman, C., Yuriev, E., & Ramsland, P. A. (2017, June 1). Antibody recognition of aberrant glycosylation on the surface of cancer cells. Current Opinion in Structural Biology. Elsevier Ltd. https://doi.org/10.1016/j.sbi.2016.10.009
Mendeley helps you to discover research relevant for your work.